Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy

Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral respons...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 140; no. 2; pp. 152 - 156
Main Authors Atanackovic, Djordje, Luetkens, Tim, Omili, Destiny, Iraguha, Thierry, Lutfi, Forat, Hardy, Nancy M, Fan, Xiaoxuan, Avila, Stephanie V, Saharia, Kapil K, Husson, Jennifer S, Niederhaus, Silke V, Margiotta, Philip, Lee, Seung T, Law, Jennie Y, Mannuel, Heather D, Vander Mause, Erica, Bauman, Sherri, Lesho, Patricia, Hankey, Kim, Baddley, John, Kocoglu, Mehmet, Yared, Jean A, Rapoport, Aaron P, Dahiya, Saurabh
Format Journal Article
LanguageEnglish
Published United States American Society of Hematology 14.07.2022
Subjects
Antibodies, Viral
COVID-19
Humans
Letters to Blood
Lymphoma
SARS-CoV-2
T-Lymphocytes
Viral Vaccines
Online AccessGet full text

Cover

More Information
Summary:Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral response to mRNA-based vaccines, patients demonstrate normal or heightened functional T-cell responses, including antiviral T-cell activity against SARS-CoV-2 variants including Omicron. Collectively, these data reinforce the importance of COVID-19 vaccination following CD19 CAR T-cell therapy, despite long-term B-cell aplasia.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.2022016175